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Background: Little is known how health related quality of life (HRQOL) change in the transition from dialysis to renal
transplantation (RTX). Longitudinal data addressing the patient-related outcomes are scarce, and particularly data
regarding kidney-specific HRQOL are lacking. Thus, the aim of the current study was to assess HRQOL in patients
followed from dialysis to RTX. Furthermore, to compare HRQOL in RTX patients and the general population.
Methods: In a prospective study, HRQOL was measured in a cohort of 110 patients (median age 53.5 (IQR 39–62) years,
GFR 54 (45–72) ml/min/1.73 m2) in dialysis and after RTX using the self-administered Kidney Disease and Quality of Life
Short Form version 1.3 (KDQOL-SF). Generic HRQOL in the RTX patients was compared to that of the general population
(n = 5903) using the SF-36. Clinical important change after RTX was defined as difference in HRQOL of SD/2.
Results: Follow-up time was 55 (IQR 50–59) months, and time after RTX was 41 (34–51) months. Four of nine domains
in kidney-specific HRQOL improved after RTX, i.e. burden of kidney disease, effect of kidney disease, symptoms and work
status. In SF-36, general health, vitality, social function and role physical improved after RTX, but none of the domains
improved sufficiently to be regarded as clinically relevant change. There were highly significant differences in HRQOL
between RTX patients and the general population after adjustment for age and gender for all items of SF-36 except for
bodily pain and mental health.
Conclusions: HRQOL improved in the transition from dialysis to transplantation, but clinical relevant change was only
obtained in the kidney specific domains. HRQOL was perceived considerably poorer in RTX patients than in the general
population. Our observations point to the need of improving HRQOL even after RTX, and should encourage further
longitudinal research and clinical attention during treatment shift.
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Patients with end stage renal disease (ESRD) dependent
on dialysis have reduced quality of life not only compared
to the general population [1-4], but also to patients with
other chronic diseases [5,6]. Kidney transplantation (RTX)
is considered to be the optimal treatment for patients with
ESRD with survival advantage compared to dialysis [7,8].
Cross-sectional studies have indicated improvement in
physical, mental and social aspects of health related qual-
ity of life (HRQOL) in patients after RTX compared to
dialysis treatment [9,10]. However, there is a scarcity of
longitudinal studies addressing HRQOL during treatment* Correspondence: n.v.d.lippe@medisin.uio.no
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article, unless otherwise stated.shift from dialysis to RTX. The few studies suggest im-
proved HRQOL, but most have a short follow-up time
and a low number of patients [11-13]. The majority of the
studies have used only generic HRQOL measures, and the
limited numbers of studies using kidney-specific question-
naires included few patients with short follow-up [4,14,15].
Furthermore, perceptions of mental and physical aspects of
HRQOL may change with time after transplantation
[16-18]. We postulate that HRQOL will improve in the
transition from dialysis to RTX, and that this applies not
only for generic, but also for disease-specific issues.
Whether kidney transplanted patients will obtain the
same HRQOL as that of the general population is un-
clear, as previous observations are inconsistent, with some
reporting inferior [19-21], and others similar HRQOLCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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As renal transplanted patients may face new encounters
such as side effects of a heavy drug regimen, infections
and deteriorating graft function [23], we expect self-
perceived HRQOL to be lower in RTX patients than in
the general population.
Thus, the aims of the current longitudinal cohort study
were to assess changes in HRQOL in the transition from
dialysis to renal transplantation, and to compare HRQOL
in transplanted patients with that of the general population.Methods
Between August 2005 and February 2007, a total of 301
patients from 10 different hospitals in Norway were in-
cluded in a cross-sectional study. All patients >18 years re-
ceiving either hemodialysis (HD) or peritoneal dialysis
(PD) for > two months were invited to participate [2]. Cog-
nitive dysfunction, major psychiatric disorder and inad-
equate Norwegian language skills were exclusion criteria.
Hospitalization during the investigation period led to ex-
clusion, but patients could be enrolled four weeks or more
after hospital discharge if they were clin0069cally stable.
Close to one third of the prevalent dialysis population
from both urban and rural areas were enrolled in the
study. Study nurses and physicians had been trained in ap-
plying the study instruments to the patients. The ques-
tionnaires were answered during a regular HD session or
during a scheduled visit for the PD patients. Further de-
tails regarding this study are given elsewhere [2].
All included patients from the first study were invited
to participate in the follow-up study, both patients who
had been transplanted as well as patients who remained
in dialysis (Figure 1). Inclusion and exclusion criteria
were unchanged from the original study. The trans-
planted patients answered the questionnaires during a
regular visit at the renal outpatient clinic. Clinical and
demographic data were collected from hospital charts
and/or direct questioning of the patients. Records of RTX
were obtained from the Norwegian Renal Registry [24].
Comorbidity was assessed using the modified Charlson
comorbidity index (CCI) [25]. The modified CCI is vali-
dated for dialysis patients [25] and kidney transplanted
patients [26], and is a composite score of age and 17
weighted comorbid conditions including coronary artery
disease, congestive heart failure, cerebrovascular disease,
diabetes, malignancy and chronic pulmonary disease. In
the current study all types of skin cancers, including basal
cell carcinomas, were considered as tumors and given two
points. Hepatitis without cirrhosis was regarded as mild
liver disease. Diabetes as a comorbid condition scored one
point, diabetes as cause of ESRD scored two points. CCI
was also calculated without including age to evaluate the
effect of age as a separate factor in statistical analyses.Data on HRQOL in the general population were collected
in the Survey of Level of Living 2002 [27].
The Regional Committees for Medical and Health
Research Ethics in Norway approved the protocols (2005/
2010), and concession was obtained from the National Data
Inspectorate. The study was accomplished according to the
Helsinki Declaration [28]. Written and oral information
were provided, and signed consent was obtained.
HRQOL
The self-administered Kidney Disease and Quality of Life
Short Form version 1.3 (KDQOL-SF) [29] consists of a
kidney-specific and a generic part. The kidney-specific
part contains 43 kidney-specific items that are summa-
rized into 11 domains, i.e. symptoms, effect of kidney
disease, burden of kidney disease, cognitive function,
quality of social interaction, sleep, sexual function, social
support, dialysis staff encouragement, patient satisfaction
with care, as well as work status. The kidney-specific do-
mains “dialysis staff encouragement” and “satisfaction
with care” were not relevant in RTX patients, and thus
excluded from the current analyses. One item, the over-
all health rating item, is not included in the 11 prede-
fined domains of the KDQOL. Respondents rate their
health on a 0 – 10 response scale ranging from worst
possible to best possible health. The score was converted
to a 0–100 score, where 100 was the best perceived
overall health. The generic part of KDQOL-SF comprises
the Medical Outcome Study 36-item Short Form Health
Survey (SF-36) [30]. It consists of 36 items summarized into
the eight conceptual domains physical function, limitation
due to physical problems, bodily pain, general health, vital-
ity, social function, limitation due to emotional problems,
and mental health. Two component summary scores can
be derived from the subscales, physical component sum-
mary score (PCS) and mental component summary score
(MCS). Scores in KDQOL-SF were transformed into linear
0–100 point scores, with higher scores indicating better
quality of life. KDQOL-SF has been validated for kidney
transplanted patients and dialysis patients, also for use in
longitudinal studies [31,32].
Half a standard deviation (SD) of the baseline score in
each domain was chosen as a measure of clinical rele-
vant change in HRQOL [33]. This is equivalent to
Cohen’s d = 0.50 [34].
Statistical methods
Clinical and demographical data were presented either as
mean ± SD if normally distributed, or as median with inter-
quartile range (IQR) if data were skewed. Proportions were
given for categorical variables. For normally distributed
data, paired Student t-test was applied, while Wilcoxon
signed rank tests were used if data were skewed.
McNemar’s test was used for categorical data.
Figure 1 Flowchart of enrolment.
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being skewed. Data were presented in this manner in
order to compare with other published HRQOL studies,
however, non-parametric Wilcoxon signed rank tests were
used as assumptions of normality were not fulfilled.
To evaluate whether change in HRQOL differed with
respect to age, gender, transplant function, baseline dia-
lysis modality, dialysis vintage, and time after RTX,
stratified analyses were undertaken. Comparison of dif-
ferences in delta values (change from dialysis to RTX) in
all the KDQOL-SF domains in the cited strata were per-
formed using the Student t- test as the delta values ful-
filled the assumption of normality. Cut-off for age was
set at the value ≥ 65 years and ≤ 45 years. These cut-offs
were chosen to secure diversion in age and adequate
sample sizes. Based on clinical experience and to ensure
adequate sample sizes, the cut -off values for glomerular
filtration rate (GFR), for time after RTX, and for dialysis
vintage were set at 45 ml/min/1.73 m2, 36 months, and
12 months, respectively. Dialysis vintage was defined as
the time from the first dialysis sessions until baseline.
Forward selection logistic regression models were built
to identify predictors of clinical improvement of HRQOL
after RTX compared to dialysis. Analyses were undertaken
with the separate domains of KDQOL and SF-36 as
dependent variables. The dependent variables were dichot-
omized based on the cut-off for clinical relevant change as
described previously, i.e. delta values ≥ 0.5 SD. Gender, co-
morbidity, BMI, dialysis vintage and travel time to dialysis
center were chosen as independent variables to assess pre-
dictors of improved HRQOL after RTX. The independentvariables were categorized to fulfill the assumption of lin-
earity of the logit. The cut-offs were set clinically at age ≥
65 and ≤ 45 years, travel time to dialysis center ≥ 45 mi-
nutes, dialysis vintage ≥ 12 months, comorbidity ≥ 4 points
and BMI ≥ 30 kg/m2.
Based on the mean reference values of the general popu-
lation, expected mean scores were calculated, meaning the
HRQOL scores that would be observed in the general
population if they had equivalent age and gender distribu-
tion as the RTX patients [35]. Non-parametric one-sample
test was used to compare the expected median scores with
the crude median scores of the RTX group.
Missing values in SF-36 were substituted with the pa-
tient’s mean score if less than half of the subscales were
missing. No substitution was done in KDQOL if a ques-
tion was left open, the total score was calculated as sug-
gested by the RAND group [36]. Missing data were
treated by pair wise deletion in the statistical analyses.
All data were analysed using SPSS for Windows ver-
sion 21 (IBM SPSS Statistics, New York, USA). Level of
significance was set to p < 0.05.
Results
From the original dialysis population of 301 patients, 110
patients had been transplanted, while 142 died during the
55 months of follow-up (Figure 1). The clinical and demo-
graphic characteristics of the transplanted patients are
given in Table 1. Time since transplantation was 40.3 ±
14.4 months. Standard immunosuppressive regimen
with cyclosporine or tacrolimus and mycophenolate
mofetil (MMF) combined with (86/110) or without (3/110)
Table 1 Characteristics of the study population (n = 110) during dialysis and after renal transplantation
Dialysis Transplanted P value
Age 51.3 ± 14.8 56.6 ± 14.7
Female gender, % 33.6
Hemodialysis, % 75,5
Time of follow-up, months 55.0 ± 6.5
Time after RTX1, months 40.3 ± 14. 3
Wait listed for RTX1 at baseline 36/110
Time in dialysis, months 7 (3 – 15) 22 (15 – 36)2
Glomerular filtration rate, mL/min/1.73 m2 54 (45 – 72)
Systolic blood pressure, mmHg 141 ± 21 136 ± 15 0.03
Diastolic blood pressure, mmHg 80 ± 12 78 ± 10 0.10
Body mass index, kg/m2 25.9 ± 4.2 26.8 ± 5.3 0.012
Hemoglobin, g/dL 12.2 ± 1.5 13.4 ± 1.8 < 0.001
Albumin, mmol/L 39.3 ± 4.3 42.8 ± 3.5 < 0.001
C-reactive protein, mg/L 5 (2 – 9) 2 (1 – 7) = 0.20
Cholesterol, mmol/L 4.4 ± 1.3 5.0 ± 1.2 = 0.001
Charlson Comorbidity Index 5 (3 – 6) 6 (4 – 7) < 0.001
Diabetes (n) 19 25 = 0.11
Data are given as mean ± SD, median with IQR, or number. 1Renal transplantation; 2Time in dialysis at time of transplantation.
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Everolimus combined with MMF and prednisolone was
used in 11/110 patients, and other different combinations
in 10/110 patients.
Changes in HRQOL from dialysis to RTX
Significant HRQOL improvements were seen after RTX
in several of the kidney-specific HRQOL domains. Effect
of kidney disease, burden of kidney disease, symptoms,
sleep, sexual function and work improved, while cogni-
tive function, social support and quality of social inter-
action did not (Figure 2). The kidney-specific “overall
health” item improved after RTX, from 58 ± 20 to 68 ± 21
respectively, p < 0.001. In the generic domains, significant
improvement was observed in limitation due to physical
problems, vitality, general health and social function.
Changes in HRQOL scores were not perceived different
between men and women, or between patients with low
or high GFR in the stratified analyses. Neither did changes
in HRQOL scores differ between dialysis modalities (peri-
toneal dialysis vs. hemodialysis). In age-stratified analyses,
renal transplantation had different effect on younger pa-
tients than older patients in the domain quality of social
interaction (Δ 8 ± 26 vs. Δ -5 ± 25, p = 0.035). In patients ≤
45 years the score was 76 ± 22 in dialysis and 84 ± 14 after
RTX, while in patients ≥ 65 years the score was 86 ± 16 in
dialysis and 81 ± 19 after RTX.
Patients with the longest time in dialysis had a more
pronounced change in the domain burden of kidney dis-
ease compared to patients with shorter time (Δ 42 ± 43vs. Δ 21 ± 39, p = 0.016). Patients with dialysis vintage ≥
12 months scored 33 ± 28 in dialysis and 75 ± 29 after
RTX, while patients with dialysis vintage < 12 months
scored 41 ± 25 and 63 ± 31.
Change in PCS differed between patients with shorter
time after RTX compared with patients with longer time
after RTX (Δ 8 ± 12 vs. Δ 1 ± 18, p = 0.045). Patients with
shorter time after RTX had a score of 41 ± 9 in dialysis
and 49 ± 10 at time of follow-up, and patients with lon-
ger time after RTX had a score of 41 ± 10 in dialysis and
42 ± 10 at time of follow-up. No association with time
was observed in MCS.
Clinical relevant change
The described clinical relevant improvement (half a SD)
varied from 12 to 20 points for the different domains in
KDQOL-SF, and 5 points for PCS and MCS. Using these
thresholds, the domains effect of kidney disease, burden of
kidney disease, work status, symptoms and the overall
health item improved (Figure 2). None of the generic do-
mains, including those with statistical significant changes,
had clinical relevant change from dialysis to RTX, nor did
any relevant clinical alterations occur in MCS and PCS
(Figure 2).
The proportion of patients that reported improvement
exceeding the cut-off for clinical relevant change ranged
from 30 to 61% for the various KDQOL-SF domains. To
identify predictors of the clinical relevant changes, separ-
ate logistic regression models were performed. Patients
with CCI score ≥ 4 were more likely to perceive improved
Figure 2 Mean KDQOL-SF in 110 patients during dialysis and after transplantation. *p < 0.05; **p < 0.001; 1Clinically relevant change:
improvement > 0.5 SD. QSI: Quality social interaction; Cogn: Cognitive function; EKD: Effect of kidney disease; BKD: Burden of kidney disease;
Symp: Symptoms; Sex: Sexual fuction; Soc: Social support; Work: Work status; PF: Physical function; RP: Role physical; GH: General health; VT:
Vitality; BP: Bodily pain; SF: Social functioning; MH: Mental health; RE: Role emotional; PCS: Physical Component Summary Score; MCS: Mental
Component Summary Score. Scores 0–100, higher number indicating better HRQOL.
Figure 3 Adjusted SF-36 mean values in kidney transplanted
patients (n = 110) and the general population (n = 5903).
*p < 0.05; **p≤ 0.001. PF: Physical function; RP: Role physical; GH:
General health; VT: Vitality; BP: Bodily pain; SF: Social functioning;
MH: Mental health; RE: Role emotional; PCS: Physical Component
Summary Score; MCS: Mental Component Summary Score. Scores
0–100, higher number indicating better HRQOL. Mean scores
adjusted for age and gender.
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low comorbidity score (OR = 4.5, 95% CI 1.7 – 12.3, p =
0.003). BMI ≥ 30 kg/m2 in dialysis was associated with im-
provement in mental health after RTX (OR = 4.0, 95% CI
1.3 – 12.1, p = 0.016). For other domains in KDQOL-SF,
no variables were identified that predicted improvement
in kidney-specific or generic HRQOL after RTX.
Comparison to the general population
Overall, the crude SF-36 scores in RTX patients were
statistical significantly lower than in the general popula-
tion (n = 5903) in all domains except for bodily pain and
mental health. The differences persisted after adjustment
for age and gender (Figure 3). The most pronounced
changes were found in physical function (9 points), limi-
tations in physical role functioning (23 points), general
health (17 points) and limitations in emotional role
functioning (15 points).
Discussion
An important novel observation in the present longitu-
dinal study was the overall improvement in the kidney-
specific HRQOL in transplanted patients. Kidney-specific
data have so far been lacking or insufficient. Improvement
would be expected shortly after transplantation, as the kid-
ney function is retrieved. Our observation showed that
this improvement was present after more than three years
post-RTX, and specifically the perception of complaints
related to kidney failure. The majority of the current RTX
patients had mild to moderate chronic kidney disease, i.e.
stage 2–3, and with fewer symptoms than would be ex-
pected with more advanced renal failure. The two do-
mains, i.e. effect of kidney disease (EKD) and burden of
kidney disease (BKD) had numerically the most pro-
nounced improvement after RTX. BKD, which addresseshow kidney disease may interfere with life, cause frustra-
tions, and burdening the family, and EKD, being more re-
lated to daily-life restrictions and worries, were in the
present study lower than what have been observed in a
group of never-transplanted CKD (chronic kidney disease)
patients with equivalent GFR [37]. In the latter study BKD
scores were 85 compared to 67 in our study, while EKD
scores were 92 and 82 in the never-transplanted CKD and
the RTX patients, respectively. On the other hand, our ob-
servation of the HRQOL scores in the longitudinal cohort
study was in accordance with the finding in a cross-
sectional study of kidney transplanted patients with GFR in
the same range, i.e. GFR 30–60 ml/min/1.73 m2, with un-
adjusted EKD scores 88 and BKD 78 [38]. These observa-
tions suggest that despite similar GFR, renal transplanted
may actually fare poorer than non-transplanted patients.
This assumption can only be corroborated by findings
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get prospective longitudinal HRQOL studies including pa-
tients from CKD stage 2–3 and follow them for years until
after RTX.
The KDQOL-SF has been assessed as a valid and reli-
able tool in RTX patients as well as in other CKD pa-
tients [32]. The internal consistency has been found to
be particularly high for the domains EKD, BKD and
symptoms in RTX patients [32], while some domains
may be less relevant as they contain questions specific-
ally for dialysis patients [29]. Previous experience with
the use of KDQOL-SF is, however, limited in RTX pa-
tients. As far as we know, only two longitudinal studies
using KDQOL-SF have been done, and with a small num-
ber of patients [14,15]. One of the studies was published
as a short abstract, and a small amount of data was re-
vealed. Only 30 transplanted patients were included, all
with kidney from living donors [15]. The other study in-
cluded a highly selected small group of young transplanted
patients attending a training program [14]. There are two
cross-sectional studies that have used KDQOL and com-
pared HRQOL in dialysis patients with that of RTX pa-
tients [39,40]. While one of the studies was small and
addressed ethnicity differences rather than treatment shift
[40], the other large study had less than 35% response rate
in the RTX group [39], which may lead to selection bias.
The current study therefore may contribute noticeably to
increased knowledge on kidney-specific HRQOL in the
transition from dialysis to transplantation.
Patients over 65 years of age actually perceived poorer
HRQOL in the domain “quality of social interaction” in
the conversion from dialysis to RTX, while younger pa-
tients perceived improvement. One possible explanation
to this finding could be that older patients may become
more socially isolated after RTX than younger. Older pa-
tients may have less personal contacts, a smaller network
of family and friends and thus participate more infre-
quent in social activities than younger [41,42]. Social
interaction experienced during dialysis sessions should
perhaps not be underestimated.
Dialysis vintage affected the change in the domain bur-
den of kidney disease during follow-up, with a larger im-
provement in patients with the longest time in dialysis.
This may not be surprising, as the patients with longest
dialysis vintage may have felt more burdened, and there-
fore perceived that RTX relieved the frustrations and
interference more than in those with shortest dialysis vin-
tage. Divergent results regarding associations between dia-
lysis vintage and HRQOL after RTX are reported, and
only for generic domains, i.e. physical domains [18,43,44].
One item which has gained little attention in previous
studies is the question “Overall, how would you rate
your health” in the kidney-specific part of the question-
naire. As far as we know, only one study has publisheddata on this question [39], and the authors surprisingly
found the score to be lower in transplanted than in dia-
lysis patients, with no apparent explanation. In contrast
to that finding, the current study showed substantially
improvement after RTX. This is in accordance with our
clinical experience with RTX patients, and actually con-
firms that beyond the survival benefit, patient-related
outcome is enhanced after RTX.
The changes in the generic HRQOL domains were less
impressive than the changes observed in the disease-
specific domains. The present study actually contradicted
previous reports that generic HRQOL is perceived sub-
stantial higher in RTX than in dialysis patients [22,45].
However, the majority of previous studies are cross-
sectional, and therefore selection bias cannot be excluded.
Furthermore, adjustments for other variables were rarely
undertaken in these studies. When comparing dialysis pa-
tients on the waiting list with renal transplanted patients,
the difference in HRQOL was less pronounced and quite
comparable to our study [20]. A possible explanation for
the difference in HRQOL in the different studies could be
that the majority of patients in the cross-sectional studies
would never be considered for RTX due to comorbidity or
high age [22,45]. Moreover, the only previous longitudinal
study (n = 20) using KDQOL-SF [14] actually reported
change in generic HRQOL from dialysis to transplantation
in the same range as the present study.
We cannot rule out the possibility of a time effect con-
tributing to the discrepancies of findings in our study
and in some previous studies, as those studies compar-
ing HRQOL changes from dialysis to transplantation
have been obtained in the early post-transplantation
period [4,11,17]. Less is known about HRQOL after the
initial “honeymoon” period in the transplanted patients.
In the present study, PCS was perceived lower in pa-
tients who had been transplanted for more than three
years compared to those with shorter time, but no such
difference was found for the kidney-specific items. It has
been suggested that HRQOL in kidney transplanted pa-
tients might follow a U-shaped pattern with the highest
score the first year and then after five years [46], but this
time effect needs to be further explored.
Statistical significant difference in HRQOL may not ne-
cessarily be perceived as clinical important change for the
patient. Clinically meaningful changes in HRQOL may
vary with the disease, level of severity, gender, cultural
background, socioeconomic status and other factors [47].
Furthermore, one cannot rule out that the greater change
in the most impaired patients could actually reflect a stat-
istical phenomenon, the regression to the mean, rather
than a clinical alteration. Determining clinically meaning-
ful change has been a matter of substantial debate, and
several methods, either anchor-based or distribution-
based, have been proposed to define and calculate this
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sive review [47]. Anchor-based methods compares changes
with a reference, an anchor, which can be objective mea-
sures such as response to treatment, or subjective mea-
sures such as patient-reported global ratings of change in
health status. Distribution-based methods are based on
statistical properties of the scale and include effect sizes.
One of the most common used distribution-based tools is
Cohen’s d, where the effect size (ES) is calculated from the
change in mean scores divided by the standard deviation
[34]. Cohen’s guidelines suggests that ES of 0.2 - 0.5 reflect
a small effect, 0.5 – 0.8 a moderate effect and > 0.8 a large
effect. There are no established thresholds for clinical im-
portant changes for the KDQOL-SF questionnaire, neither
for dialysis nor kidney transplanted patients. In the current
study, we chose pragmatically the distribution-based
method of half a standard deviation [33] to define the cut-
off clinical relevant change. This is equivalent to Cohen’s
d = 0.50. To evaluate whether the method used in the
current study represents the “true” threshold for these pa-
tients, more studies are needed, also combining anchor-
based and distribution based methods.
Most patients in dialysis may expect their lives to
change dramatically after transplantation, and thus over-
estimate the benefits of the transplantation [48]. Actu-
ally, the generic HRQOL scores in the current study
were overall much lower in the RTX patients then in the
general population for all domains in SF-36 except for
bodily pain and mental health. Our finding is in keeping
with a previous Norwegian study of young transplant re-
cipients [49], and with observations in other patients
with chronic diseases [50,51]. The reduced HRQOL in
RTX patients compared to the general population may
reflect that these patients although transplanted still
have a chronic kidney disease, often associated comor-
bidity, and also side effects of the medication, anxiety of
rejection, malignancy, and infections.
The longitudinal design, the fairly large sample size and
the fact that none of the patients were lost to follow-up
strengthen the present study. Data quality was good with
less than 2% missing data in SF-36. The transplantation
recruitment procedure was similar in all dialysis units, and
transplantations took place in one center. Some particular
aspects may limit the generalizability of our results as very
few patients were non-Caucasian, and the time in dialysis
before RTX was fairly short. The inclusion criteria may
have led to selection bias towards healthier patients as pa-
tients with cognitive dysfunction, drug abuse or hospital-
ized patients were excluded. although they were considered
representative of the Norwegian dialysis population [2],
Evaluation of response shift was not addressed when de-
signing the study. This is a phenomenon suggesting that
the self-perceived perceptions of HRQOL may be incited
by changes in health, e.g. transplantation, which may thenlead to changes in internal standards of measurement,
priorities or in the conceptualization of perceived
HRQOL [52].
Conclusion
While the kidney-specific HRQOL improved statistically
and clinically in the transition from dialysis to transplant-
ation, the changes in generic HRQOL items were not large
enough to be regarded as clinically important change. Fur-
thermore, RTX patients did not obtain HRQOL similar to
that of the general population. We suggest that patient-
related outcomes such as kidney-specific and generic
HRQOL should be used routinely in RTX patients in the
clinical setting, and not only for research purpose. This
will provide important information about the well-being
of these patients. Health professionals should be aware of
the reduced HRQOL in patients with ESRD, which may
persist even after RTX, and focus on how HRQOL could
be improved. We recommend that not only should
HRQOL, including kidney-specific items, be measured in
patients with CKD 4–5, but also annually after the initi-
ation of dialysis. Repeated measurements should also be
undertaken after the conversion to RTX. Future clinical
trials with longitudinal design and repeated measurements
of HRQOL are required to better describe the trajectory
after renal transplantation.
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